Better Outcomes with Precision Medicine.
Final results from MOSCATO-01, a prospective precision medicine-based trial, indicate that molecular profiling improves outcomes for patients with diverse types of advanced cancer. Compared with previous nontargeted therapy, progression-free survival was extended by 30% in a third of patients whose treatment was tailored to their tumor's genetic makeup.